Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Optimizing ECT for difficult-to-treat depression

Official title: Changing Tactics? Optimizing ECT in Difficult-to-treat Depression: A Randomized Trial Comparing Continuation of Right Unilateral ECT and Switching to Bitemporal ECT in Case of Early Non-response During an Acute Course of ECT for Difficult-to-treat Depression

Run by Universitaire Ziekenhuizen KU Leuven · NCT05923801 · Data updated 2026-11-12

This study is testing whether sticking with one type of electroconvulsive therapy or switching to another can help people with tough-to-treat depression recover faster and with less impact on their thinking.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment196 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Locations1 site (Kortenberg)
StatusRecruiting
StartedJune 1, 2023
Main results expectedJune 1, 2026
Study endsJune 1, 2026
Registry record updatedMay 11, 2026
Trial IDNCT05923801 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older diagnosed with major depressive disorder or bipolar disorder who have not shown a significant response to initial ECT treatments.

Probably not a fit

Patients with contraindications for general anesthesia, non-Dutch speakers, or those with certain psychiatric disorders such as schizophrenia will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial aims to determine whether continuing with right unilateral (RUL) electroconvulsive therapy (ECT) or switching to bitemporal (BT) ECT is more effective in speeding up recovery and minimizing cognitive impact for patients with difficult-to-treat depression who show no early response to treatment. Participants will be assessed for antidepressant efficacy and cognitive performance during the acute ECT course and up to three months post-treatment. The study will involve patients diagnosed with major depressive disorder or bipolar disorder who have not responded adequately after four ECT sessions.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies for patients with difficult-to-treat depression, enhancing recovery rates while preserving cognitive function.

How similar studies have gone: Other studies have explored ECT techniques, but this specific comparison of RUL versus BT ECT in early non-responders is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
* Age 18 or older
* Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84).

Exclusion Criteria:

* Contra-indication for general anesthesia
* Non-Dutch speaking
* Diagnosis of schizoaffective disorder or schizophrenia
* Diagnosis of substance use disorder in the past six months
* Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score \<23
* Previous ECT course in the past three months
* Participation in an interventional Trial with an investigational medicinal product or device
* Pregnancy

Where it's running

  • UPC Kortenberg
    Kortenberg, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.